Phase 2 Acute Myeloid Leukaemia Clinical Trials
30 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 30 trials
Recruiting
Phase 2Phase 3
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1Phase 2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic LeukaemiaAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 1Phase 2
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University72 enrolled1 locationNCT06621212
Not Yet Recruiting
Phase 2
ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol.
Acute Myeloid Leukaemia
Australasian Leukaemia and Lymphoma Group50 enrolled1 locationACTRN12625000994482
Recruiting
Phase 1Phase 2
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukaemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20 enrolled1 locationNCT07036250
Recruiting
Phase 2
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Myelodysplastic SyndromeAcute Myeloid LeukaemiaRecipients of Allogeneic Stem Cell Transplantation+1 more
Vastra Gotaland Region100 enrolled5 locationsNCT06793410
Active
Phase 2
AMLM27/ IMpress_001: A phase II study evaluating the efficacy and safety of Imetelstat in Patients with high-risk (HR) myelodysplastic syndromes (MDS) or Acute Myeloid Leukaemia (AML) failing HMA-based therapy.
Myelodysplastic SyndromesAcute Myeloid Leukaemia
Australasian Leukaemia & Lymphoma Group6 enrolled5 locationsACTRN12625000226404
Recruiting
Phase 2
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
MDS (Myelodysplastic Syndrome)Acute Myeloid LeukaemiaMPN (Myeloproliferative Neoplasms)
Istituto Clinico Humanitas42 enrolled2 locationsNCT06892223
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University34 enrolled1 locationNCT06434662
Recruiting
Phase 2
AMLM26/T1 INTERCEPT: A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics - Gilteritinib+ Venetoclax
Acute Myeloid Leukaemia
Australasian Leukaemia and Lymphoma Group45 enrolled16 locationsACTRN12624000082505
Not Yet Recruiting
Phase 2
AMLM28 Platform Trial - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT)
Acute Myeloid Leukaemia
Australasian Leukaemia and Lymphoma Group (ALLG)400 enrolled1 locationACTRN12623000900617
Withdrawn
Phase 2
ALLG AMLM28/D1: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - Domain 1
Acute Myeloid Leukaemia
Australasian Leukaemia and Lymphoma Group (ALLG)50 enrolled1 locationACTRN12623000851662
Not Yet Recruiting
Phase 2
MDS05/D2 - Phase Ib/II study for treatment of Myelodysplasia (MDS) with SRA515 and ASTX727,
Myelodysplastic Syndrome (MDS)Acute Myeloid Leukaemia (AML)
Australasian Leukaemia and Lymphoma Group (ALLG)86 enrolled1 locationACTRN12622001302741
Recruiting
Phase 2
A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation
transformed AML/ MDSMyeloproliferative DisordersHodgkin's Disease+4 more
St Vincent's Hospital, Sydney127 enrolled10 locationsACTRN12622001232729
Not Yet Recruiting
Phase 2
AMLM22/D3 - The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.
Acute Myeloid Leukaemia (AML)
Australian Leukaemia and Lymphoma Group (ALLG)50 enrolled1 locationACTRN12621000246886
Active
Phase 2
A study investigating different combinations of Cytarabine, Midostaurin, Pracinostat and Venetoclax in elderly patients with Acute Myeloid Leukaemia to extend remission.
Acute Myeloid Leukaemia
The Australasian Leukaemia and Lymphoma Group208 enrolled1 locationACTRN12619001655134
Recruiting
Phase 2
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).
Acute Myeloid Leukaemia (AML)
Australian Leukaemia and Lymphoma Group (ALLG)75 enrolled19 locationsACTRN12619000280101
Recruiting
Phase 2
Efficacy of Slow Tempo Inductions and Maintenance using Low Dose Cytarabine and Thioguanine: Single arm study.
Newly diagnosed Acute Myeloid LeukaemiaRelapsed or Refractory Acute Myeloid Leukaemia
Northern Sydney local Health District30 enrolled1 locationACTRN12617000231347